We demonstrated that KIF20A was overexpressed in NSCLC specimens compared with the adjacent non-tumorous specimens, and high expression of KIF20A was associated with clinical stage and metastasis in NSCLC.
Moreover, high expression of these 2 KIF members was significantly associated with advanced clinical stage (OR = 1.98, 95% CI: 1.57-2.50, P < .001; OR = 2.63, 95% CI: 2.03-3.41, P < .001, respectively), positive lymph node metastasis (OR = 2.32, 95% CI: 1.65-3.27, P < .001; OR = 2.13, 95% CI: 1.59-2.83, P < .001, respectively), and distant metastasis (OR = 2.20, 95% CI: 1.21-3.99, P = .010; OR = 5.25, 95% CI: 2.82-9.77, P < .001, respectively); only high KIF20A expression was related to poor differentiation grade (OR = 1.82, 95% CI: 1.09-3.07, P = .023).
KIF20A protein expression was highly correlated with International Federation of Gynecology and Obstetrics stage (<i>P</i>=0.008), lymph node metastasis (<i>P</i>=0.002), intraperitoneal metastasis (<i>P</i><0.001), vital status at last follow-up (<i>P</i><0.001), intraperitoneal recurrence (<i>P</i>=0.030), tumor recurrence (<i>P</i>=0.005), drug resistance (<i>P</i>=0.013), and ascites with tumor cells (<i>P</i><0.001).
Statistical analysis revealed that high KIF20A expression was significantly associated with gender (P = 0.046), clinical stage (P<0.001), T category (P = 0.022), N category (P<0.001), distant metastasis (P = 0.001) and vital status (P = 0.001).